Up to 72% of patients stayed on a liver treatment for a year
Madrigal Pharmaceuticals (MDGL) reported real-world study results for Rezdiffra at AASLD. Up to 93% of patients showed liver stiffness improvement, 72% remained on treatment for a year, and safety findings aligned with trials. Improvements were seen across diverse patient groups, including those using GLP-1 therapies.
How this was made
The 30-second read
Why it matters
The data shows high treatment persistence and consistent improvements in liver stiffness, ALT, LDL, and triglycerides, supporting the drug's commercial potential.
Market read
First public disclosure of real‑world effectiveness may drive short‑term buying interest in MDGL.
What to watch
Potential competition from other MASH candidates and payer coverage decisions could temper upside.
Background
Madrigal Pharmaceuticals (MDGL) focuses on metabolic dysfunction‑associated steatohepatitis (MASH). The company released real‑world evidence from multiple U.S. data sources presented at the AASLD Liver Meeting.
Ticker impact
Madrigal announced real‑world study results showing up to 72% of patients stayed on Rezdiffra for a year with improved liver metrics.
upward pressure as investors price in stronger commercial traction
First disclosure of robust real‑world outcomes; market typically reacts positively to efficacy and persistence data for biotech drugs.
Market effects
Strengthens the MASH therapeutic segment and may boost peer biotech valuations.
U.S. biotech investors may increase exposure to liver‑disease pipelines.
Limited to biotech sector; no broad market effect.
Counterpoint
Real‑world data may not translate to sales if reimbursement or pricing issues arise.
Key entities
- companyMadrigal Pharmaceuticals
Biopharma developing Rezdiffra for MASH.
- drugRezdiffra
Resmetirom, a therapy for MASH.
